Page 424 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

402 PART IV Specific Malignancies in the Small Animal Patient

202. Serra Varela JC, Pecceu E, Handel I, et al.: Tolerability of a rapid- 222. Lin TY, Fenger J, Murahari S, et al.: AR-42, a novel HDAC inhibi-
escalation vinblastine-prednisolone protocol in dogs with mast cell tor, exhibits biologic activity against malignant mast cell lines via
tumours, Vet Med Sci 2:266–280, 2016. down-regulation of constitutively activated Kit, Blood 115:4217–
VetBooks.ir 203. Ma Y, Longley BJ, Wang X, et al.: Clustering of activating muta- 223. Nagamine MK, Sanches DS, Pinello KC, et al.: In vitro inhibitory
4225, 2010.
tions in c-KIT’s juxtamembrane coding region of canine mast cell
neoplasms, J Invest Dermatol 112:165–170, 1999.
204. Liao AT, Chien MB, Shenoy N, et al.: Inhibition of constitutively effect of trichostatin A on canine grade 3 mast cell tumor, Vet Res
Commun 35:391–399, 2011.
active forms of mutant kit by multitargeted indolinone tyrosine 224. Lin TY, Bear M, Du Z, et al.: The novel HSP90 inhibitor STA-
kinase inhibitors, Blood 100:585–593, 2002. 9090 exhibits activity against Kit-dependent and -independent
205. Pryer NK, Lee LB, Zadovaskaya R, et al.: Proof of target for malignant mast cell tumors, Exp Hematol 36:1266–1277, 2008.
SU11654: inhibition of KIT phosphorylation in canine mast cell 225. London CA, Bear MD, McCleese J, et al.: Phase I evaluation of
tumors, Clin Cancer Res 9:5729–5734, 2003. STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in
206. London CA, Malpas PB, Wood-Follis SL, et al.: Multi-center, pla- dogs with spontaneous cancer, PLoS One 6:e27018, 2011.
cebo-controlled, double-blind, randomized study of oral toceranib 226. Pinello KC, Nagamine M, Silva TC, et al.: In vitro chemosensitiv-
phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the ity of canine mast cell tumors grades II and III to all-trans-retinoic
treatment of dogs with recurrent (either local or distant) mast cell acid (ATRA), Vet Res Commun 33:581–588, 2009.
tumor following surgical excision, Clin Cancer Res 15:3856–3865, 227. Ohashi E, Miyajima N, Nakagawa T, et al.: Retinoids induce
2009. growth inhibition and apoptosis in mast cell tumor cell lines, J Vet
207. Weishaar KM, Ehrhart EJ, Avery AC, et al.: c-Kit mutation and Med Sci 68:797–802, 2006.
localization status as response predictors in mast cell tumors in dogs 228. Miyajima N, Watanabe M, Ohashi E, et al.: Relationship between
treated with prednisone and toceranib or vinblastine, J Vet Intern retinoic acid receptor alpha gene expression and growth-inhibitory
Med 32:394–405, 2018. effect of all-trans retinoic acid on canine tumor cells, J Vet Intern
208. Tjostheim SS, Stepien RL, Markovic LE, et al.: Effects of toceranib Med 20:348–354, 2006.
phosphate on systolic blood pressure and proteinuria in dogs, J Vet 229. Elders RC, Baines SJ, Catchpole B: Susceptibility of the C2 canine
Intern Med 30:951–957, 2016. mastocytoma cell line to the effects of tumor necrosis factor-related
209. London C, Mathie T, Stingle N, et al.: Preliminary evidence for apoptosis-inducing ligand (TRAIL), Vet Immunol Immunopathol
biologic activity of toceranib phosphate (Palladia((R))) in solid 130:11–16, 2009.
tumours, Vet Comp Oncol 10:194–205, 2012. 230. Peter B, Gleixner KV, Cerny-Reiterer S, et al.: Polo-like kinase-1
210. Hahn KA, Ogilvie G, Rusk T, et al.: Masitinib is safe and effec- as a novel target in neoplastic mast cells: demonstration of growth-
tive for the treatment of canine mast cell tumors, J Vet Intern Med inhibitory effects of small interfering RNA and the Polo-like
22:1301–1309, 2008. kinase-1 targeting drug BI 2536, Haematologica 96:672–680,
211. Hahn KA, Legendre AM, Shaw NG, et al.: Evaluation of 12- and 2011.
24-month survival rates after treatment with masitinib in dogs with 231. London CA, Gardner HL, Rippy S, et al.: KTN0158, a human-
nonresectable mast cell tumors, Am J Vet Res 71:1354–1361, 2010. ized anti-KIT monoclonal antibody, demonstrates biologic activity
212. Isotani M, Ishida N, Tominaga M, et al.: Effect of tyrosine kinase against both normal and malignant canine mast cells, Clin Cancer
inhibition by imatinib mesylate on mast cell tumors in dogs, J Vet Res 23:2565–2574, 2017.
Intern Med 22:985–988, 2008. 232. Macy DW: Canine and feline mast cell tumors: biologic behav-
213. Marconato L, Bettini G, Giacoboni C, et al.: Clinicopathological ior, diagnosis, and therapy, Sem Vet Med Surg (Sm An) 1:72–83,
features and outcome for dogs with mast cell tumors and bone mar- 1986.
row involvement, J Vet Intern Med 22:1001–1007, 2008. 233. Kenyon AJ, Ramos L, Michaels EB: Histamine-induced suppressor
214. Yamada O, Kobayashi M, Sugisaki O, et al.: Imatinib elicited a macrophage inhibits fibroblast growth and wound healing, Am J
favorable response in a dog with a mast cell tumor carrying a c-kit Vet Res 44:2164–2166, 1983.
c.1523A>T mutation via suppression of constitutive KIT activa- 234. Huttunen M, Hyttinen M, Nilsson G, et al.: Inhibition of kerati-
tion, Vet Immunol Immunopathol 142:101–106, 2011. nocyte growth in cell culture and whole skin culture by mast cell
215. Bavcar S, de Vos J, Kessler M, et al.: Combination toceranib and mediators, Exp Dermatol 10:184–192, 2001.
lomustine shows frequent high grade toxicities when used for treat- 235. Saar C, Opitz M, Lange W, et al.: Mastzellenreitkulose bei katzen,
ment of non-resectable or recurrent mast cell tumours in dogs: a Berl Munch Tierarztl Wochenschr 82:438–444, 1969.
European multicentre study, Vet J 224:1–6, 2017. 236. Hadzijusufovic E, Peter B, Rebuzzi L, et al.: Growth-inhibitory
216. Burton JH, Venable RO, Vail DM, et al.: Pulse-administered toc- effects of four tyrosine kinase inhibitors on neoplastic feline mast
eranib phosphate plus lomustine for treatment of unresectable mast cells exhibiting a Kit exon 8 ITD mutation, Vet Immunol Immuno-
cell tumors in dogs, J Vet Intern Med 29:1098–1104, 2015. pathol 132:243–250, 2009.
217. Pan X, Tsimbas K, Kurzman ID, et al.: Safety evaluation of combi- 237. Isotani M, Tamura K, Yagihara H, et al.: Identification of a c-kit
nation CCNU and continuous toceranib phosphate (Palladia((R))) exon 8 internal tandem duplication in a feline mast cell tumor case
in tumour-bearing dogs: a phase I dose-finding study, Vet Comp and its favorable response to the tyrosine kinase inhibitor imatinib
Oncol 14:202–209, 2016. mesylate, Vet Immunol Immunopathol 114:168–172, 2006.
218. Robat C, London C, Bunting L, et al.: Safety evaluation of combi- 238. Isotani M, Yamada O, Lachowicz JL, et al.: Mutations in the fifth
nation vinblastine and toceranib phosphate (Palladia(R)) in dogs: a immunoglobulin-like domain of kit are common and potentially
phase I dose-finding study, Vet Comp Oncol 10:174–183, 2012. sensitive to imatinib mesylate in feline mast cell tumours, Br J Hae-
219. Carlsten KS, London CA, Haney S, et al.: Multicenter prospective matol 148:144–153, 2009.
trial of hypofractionated radiation treatment, toceranib, and pred- 239. Chastain CB, Turk MA, O’Brien D: Benign cutaneous mastocyto-
nisone for measurable canine mast cell tumors, J Vet Intern Med mas in two litters of Siamese kittens, J Am Vet Med Assoc 193:959–
26:135–141, 2012. 960, 1988.
220. Keller A, Wingelhofer B, Peter B, et al.: The JAK2/STAT5 signaling 240. Mohr FC, Dunston SK: Culture and initial characterization of the
pathway as a potential therapeutic target in canine mastocytoma, secretory response of neoplastic cat mast cells, Am J Vet Res 53:820–
Vet Comp Oncol 16:55–68, 2018. 828, 1992.
221. Kisseberth WC, Murahari S, London CA, et al.: Evaluation of the 241. Antognoni MT, Spaterna A, Lepri E, et al.: Characteristic clinical,
effects of histone deacetylase inhibitors on cells from canine cancer haematological and histopathological findings in feline mastocy-
cell lines, Am J Vet Res 69:938–945, 2008. toma, Vet Res Commun 27(suppl 1):727–730, 2003.